Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036543
Status:
COMPLETED
Last Update Posted:
2006-08-15
First Post:
2002-05-10
Brief Title:
A Study of Atrasentan in Men With Metastatic Hormone-Refractory Prostate Cancer
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic Hormone-Refractory Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None